Recurrent Gene Fusion in Ovarian Cancer
Author Information
Author(s): Julia Salzman, Robert J. Marinelli, Peter L. Wang, Ann E. Green, Julie S. Nielsen, Brad H. Nelson, Charles W. Drescher, Patrick O. Brown
Primary Institution: Stanford University School of Medicine
Hypothesis
The recurrent novel fusion transcript ESRRA-C11orf20 may play a role in the pathogenesis of a substantial fraction of serous ovarian cancers.
Conclusion
The ESRRA-C11orf20 fusion is present in about 15% of serous ovarian cancers, suggesting it could be a significant molecular marker for detection.
Supporting Evidence
- Deep sequencing identified a recurrent fusion transcript in serous ovarian cancers.
- 10 out of 67 cases tested were positive for the ESRRA-C11orf20 fusion.
- The fusion may provide a molecular marker for early detection of ovarian cancer.
Takeaway
Scientists found a new gene fusion in ovarian cancer that happens in many tumors, which could help doctors find and treat the cancer earlier.
Methodology
The study used deep paired-end sequencing of mRNA from serous ovarian cancers and confirmed findings with RT-PCR and Sanger sequencing.
Limitations
The prevalence of the fusion may be an under-estimate due to potential false negatives in PCR replicates.
Participant Demographics
The study involved patients with serous ovarian cancer from two institutions.
Statistical Information
Confidence Interval
7% to 26%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website